患有败血症的癌症患者:挪威基于人口的队列研究的预后见解
Marit Husby1, Hanne Frydenberg2, Tor Åge Myklebust3
1Molde University College, Molde, Norway.
概括
患有败血症的癌症患者的死亡率更高,特别是转移性疾病患者. 风险在年轻人,女性和格兰阴性败血症病例中最高,突出了针对性治疗的必要性.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 与非癌症患者相比,败血症对癌症患者的死亡风险更高.
- 影响这种风险增加的具体因素,如癌症类型,转移,患者人口统计和感染微生物等,需要进一步调查.
研究的目的:
- 为了调查与癌症患者的败血症相关的不同死亡风险.
- 确定癌症类型,转移状态,性别,年龄和感染微生物如何影响癌症患者的败血症相关死亡率.
主要方法:
- 在挪威进行的一项全国性队列研究 (2008-2021) 分析了因败血症住院的成年患者.
- 关于癌症状况,败血症和医院死亡率的数据是从挪威患者登记册 (ICD-10代码) 中提取的.
- 多变量回归模型被用来计算不同亚组的医院死亡率的绝对和相对风险.
主要成果:
- 该研究包括222,832名败血症患者,其中16.9%患有癌症.
- 癌症患者的住院死亡率较高:非转移性疾病为16.2-16.9%,转移性疾病为26.2-27.1%.
- 与非癌症患者相比,癌症患者的住院死亡调整后的相对风险 (RR) 显著更高 (1.39-2.75),转移性疾病显示最高的RR (高达2.75).
- 死亡风险在年轻成年人中特别高 (例如,女性18-39岁:RR 8.28) 和那些患有格兰阴性败血症的人.
结论:
- 患有败血症的癌症患者的医院死亡率增加受到癌症类型和转移的存在的显著影响.
- 在女性,年轻人和格兰氏阴性败血症患者中观察到的死亡率最高.
- 了解这些特定的风险因素可以改善癌症患者的护理,并为开发向性败血症治疗提供信息.
相关概念视频
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Rous Sarcoma Virus (RSV) and Cancer
6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.1K
Cancers Originate from Somatic Mutations in a Single Cell
14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K


